Exonate announces CLEAR-DE trial for EXN407
Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy
Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership
The companies will focus their joint effort on extended-release therapies for ocular disease
Biomarkers of microvascular retinal perfusion indicating coronary heart disease
Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography
Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI
According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”
Fungal infection and vision impact in patients with diabetic eye disease
Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop
The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension
Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)
The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests
Q&A: Early research findings and clinical experiences with a new multifocal IOL
Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens
Secondhand smoke is environmental risk factor in myopia development, study suggests
The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Clareon Panoptix Pro IOL (Alcon) approved in Canada
The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued
A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.
Nationwide free transport for cataract patients through SpaMedica
SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.
Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration
The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD
Long-duration spaceflight tests the limits of telemedicine
In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained
Interdisciplinary report illuminates demographic, systemic health factors of dry eye disease
Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40
Patients with high genetic risk of AMD should avoid instant coffee, investigators say
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption
How a newly defined category of IOLs can benefit patient outcomes
A new functional classification can help achieve precise vision goals
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.
Refining what clinicians see and treat in outer retinal disease with Christine Curcio, PhD
Christine A. Curcio, PhD, shares an update on histology and its critical role in advancing <3 μm optical coherence tomography interpretation
Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME
The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.
Custom matching IOLs is key to managing patient satisfaction
Johann Krüger, MD, shares insights from 26 years of experience
Myopia’s global impact, by the numbers
The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050
A new set of guidelines for implementing interventional glaucoma
The framework covers ocular hypertension to severe progression
